Agios director granted options and RSUs

AGIOS PHARMACEUTICALS, INC. director Catherine Owen Adams reported equity compensation activity involving stock options, restricted stock units (RSUs), and common shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS, INC. director Catherine Owen Adams reported equity compensation activity involving stock options, restricted stock units (RSUs), and common shares. She exercised RSUs to receive 2,816 shares of common stock, bringing her direct common stock holdings to 10,865 shares.

On the same date she was granted 14,950 stock options with a $34.16 exercise price, vesting fully on June 18, 2027, and 2,927 RSUs that also vest in full on June 18, 2027. Footnotes state earlier RSUs granted June 18, 2025 vested June 18, 2026, with shares delivered within three business days.

Insider Trade Summary

2,816 shares exercised/converted

Exercise 4 txns

Insider Owen Adams Catherine

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted stock units	2,816	$0.00	$0.00
Grant/Award	Restricted stock units	2,927	$0.00	$0.00
Grant/Award	Stock options (right to buy)	14,950	$0.00	$0.00
Exercise	Common stock	2,816	$0.00	$0.00

Holdings After Transaction: Restricted stock units — 2,927 contracts (Direct); Stock options (right to buy) — 14,950 contracts (Direct); Common stock — 10,865 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Key Figures

RSUs exercised into common stock: 2,816 shares Common shares held after transactions: 10,865 shares Stock options granted: 14,950 options +5 more

8 metrics

RSUs exercised into common stock 2,816 shares Restricted stock units converted to common stock

Common shares held after transactions 10,865 shares Direct ownership following Form 4 transactions

Stock options granted 14,950 options Grant of stock options on June 18, 2026

Option exercise price $34.16 per share Stock options (right to buy) grant terms

RSUs granted 2,927 units Restricted stock units granted June 18, 2026

Option vesting date June 18, 2027 100% of underlying option shares vest on this date

RSU vesting date (2026 grant) June 18, 2027 All shares underlying 2026 RSUs vest on this date

Option expiration date June 18, 2036 Expiration for 14,950 stock options granted

Key Terms

Restricted stock units, Stock options (right to buy, Exercise or conversion of derivative security, Grant, award, or other acquisition, +1 more

5 terms

Restricted stock units financial

"The restricted stock units were granted on June 18, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock options (right to buy financial

"Stock options (right to buy) with an exercise price of 34.1600."

Exercise or conversion of derivative security financial

"Transaction code description: Exercise or conversion of derivative security."

Grant, award, or other acquisition financial

"Transaction code description: Grant, award, or other acquisition."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AGIO director Catherine Owen Adams report on this Form 4?

Catherine Owen Adams reported equity compensation activity, including exercising restricted stock units into 2,816 common shares and receiving new grants of stock options and RSUs. These transactions increased her direct common stock holdings to 10,865 shares in Agios Pharmaceuticals, Inc.

How many AGIO common shares does Catherine Owen Adams now hold directly?

After the reported transactions, Catherine Owen Adams holds 10,865 shares of Agios common stock directly. This figure reflects shares received from exercising restricted stock units and represents her updated direct ownership position reported in the Form 4 filing.

What stock options were granted to Catherine Owen Adams by AGIO?

She was granted 14,950 stock options, each with a $34.16 exercise price, expiring June 18, 2036. According to the footnotes, all of these options vest as to 100% of the underlying shares on June 18, 2027, subject to the grant terms.

What restricted stock units did Catherine Owen Adams receive from AGIO?

She received 2,927 restricted stock units, each representing a contingent right to one common share. Footnotes state these RSUs were granted June 18, 2026 and will vest in full on June 18, 2027, with vested shares delivered within three business days after vesting.

How many restricted stock units did Catherine Owen Adams exercise into AGIO shares?

She exercised 2,816 restricted stock units into an equal number of common shares. Footnotes explain these RSUs were granted June 18, 2025 and vested June 18, 2026, with vested shares scheduled for delivery within three business days after vesting.

Are Catherine Owen Adams’s AGIO equity transactions open-market buys or sales?

The filing shows no open-market purchases or sales. All reported transactions are equity compensation events, including a derivative exercise of restricted stock units and new grants of stock options and RSUs, which are typical for director compensation packages.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 05:21 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Owen Adams Catherine

(Last)

(First)

(Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	06/18/2026		M		2,816	A	$0	10,865	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted stock units	⁽¹⁾	06/18/2026		M			2,816	⁽²⁾	⁽²⁾	Common stock	2,816	$0	0	D
Restricted stock units	⁽¹⁾	06/18/2026		A		2,927		⁽³⁾	⁽³⁾	Common stock	2,927	$0	2,927	D
Stock options (right to buy)	$34.16	06/18/2026		A		14,950		⁽⁴⁾	06/18/2036	Common stock	14,950	$0	14,950	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Remarks:

	/s/ William Cook, as attorney-in-fact for Catherine Owen	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR